Basic Information
| LncRNA/CircRNA Name | B3GALT5-AS1 |
| Synonyms | NA |
| Region | GRCh38_21:39597147-39612821 |
| Ensemble | ENSG00000184809 |
| Refseq | NR_026542 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR |
| Sample | The human normal gastric epithelial cell lines GES-1, GC cell lines AGS, HGC-27, BGC-823, SGC-7901, MKN-45, blood |
| Expression Pattern | up-regulated |
| Function Description | B3GALT5-AS1 level was markedly richer in GC patients than that in normal people (P < .001). B3GALT5-AS1 may be served as a diagnostic marker for distinguishing GC patients from healthy people, and the proportion under the receiver operating characteristics curve is 0.816 (95% confidence interval, 0.758- 0.874; P = .03). Further exploration validated that high serum B3GALT5-AS1 level was related to TNM stage (P = .024), and lymph node metastasis (P = .023) |
| Pubmed ID | 31338903 |
| Year | 2019 |
| Title | Abnormally expressed long noncoding RNA B3GALT5-AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer |
External Links
| Links for B3GALT5-AS1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |